These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 8186345)
41. Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn's disease: a randomized controlled trial. Savarino E; Bodini G; Dulbecco P; Assandri L; Bruzzone L; Mazza F; Frigo AC; Fazio V; Marabotto E; Savarino V Am J Gastroenterol; 2013 Nov; 108(11):1731-42. PubMed ID: 24019080 [TBL] [Abstract][Full Text] [Related]
42. Azathioprine is more effective than mesalazine at preventing recurrent bowel obstruction in patients with ileocecal Crohn's disease. Vidigal FM; de Souza GS; Chebli LA; da Rocha Ribeiro TC; Furtado MC; Castro AC; Pinto AL; do Valle Pinheiro B; de Lima Pace FH; Machado de Oliveira J; de Oliveira Zanini KA; Gaburri PD; Zanini A; Ribeiro LC; Chebli JM Med Sci Monit; 2014 Nov; 20():2165-70. PubMed ID: 25370731 [TBL] [Abstract][Full Text] [Related]
43. [Drug safety, acceptance and effectiveness of 5-aminosalicylic acid (mesalazine) in the treatment of ulcerative colitis and Crohn disease]. Bayerdörffer E; Bock H Leber Magen Darm; 1988 Apr; 18(2):104-13. PubMed ID: 3374251 [TBL] [Abstract][Full Text] [Related]
44. Review article: new developments in the use of 5-aminosalicylic acid in patients with inflammatory bowel disease. Thomson AB Aliment Pharmacol Ther; 1991 Oct; 5(5):449-70. PubMed ID: 1793778 [TBL] [Abstract][Full Text] [Related]
45. Mesalamine capsules for the treatment of active Crohn's disease: results of a 16-week trial. Pentasa Crohn's Disease Study Group. Singleton JW; Hanauer SB; Gitnick GL; Peppercorn MA; Robinson MG; Wruble LD; Krawitt EL Gastroenterology; 1993 May; 104(5):1293-301. PubMed ID: 8482443 [TBL] [Abstract][Full Text] [Related]
46. [Azathioprine and 5-ASA in the prevention of postoperative recurrence of Crohn's disease]. Nos P; Hinojosa J; Aguilera V; Molés JR; Pastor M; Ponce J; Berenguer J Gastroenterol Hepatol; 2000 Oct; 23(8):374-8. PubMed ID: 11227650 [TBL] [Abstract][Full Text] [Related]
47. Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Riley SA; Mani V; Goodman MJ; Herd ME; Dutt S; Turnberg LA Gut; 1988 May; 29(5):669-74. PubMed ID: 2899536 [TBL] [Abstract][Full Text] [Related]
48. Tailored treatment according to early post-surgery colonoscopy reduces clinical recurrence in Crohn's disease: a retrospective study. Baudry C; Pariente B; Lourenço N; Simon M; Chirica M; Cattan P; Munoz-Bongrand N; Gornet JM; Allez M Dig Liver Dis; 2014 Oct; 46(10):887-92. PubMed ID: 25081846 [TBL] [Abstract][Full Text] [Related]
49. Mesalazine as a maintenance treatment in Crohn's disease: is it the long awaited solution? Sahmoud T; Mary JY; Sahmoud T Gut; 1997 Feb; 40(2):284-5. PubMed ID: 9071946 [No Abstract] [Full Text] [Related]
50. Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties. Tromm A; Griga T; May B Hepatogastroenterology; 1999; 46(30):3124-35. PubMed ID: 10626173 [TBL] [Abstract][Full Text] [Related]
51. Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. Courtney MG; Nunes DP; Bergin CF; O'Driscoll M; Trimble V; Keeling PW; Weir DG Lancet; 1992 May; 339(8804):1279-81. PubMed ID: 1349676 [TBL] [Abstract][Full Text] [Related]
53. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. Rachmilewitz D BMJ; 1989 Jan; 298(6666):82-6. PubMed ID: 2563951 [TBL] [Abstract][Full Text] [Related]
54. Maintenance treatment for Crohn's disease: has the time arrived? Goldstein F Am J Gastroenterol; 1992 May; 87(5):551-6. PubMed ID: 1350706 [No Abstract] [Full Text] [Related]
55. Oral 5-aminosalicylic acid preparations in treatment of inflammatory bowel disease. An update. Martin F Dig Dis Sci; 1987 Dec; 32(12 Suppl):57S-63S. PubMed ID: 2891469 [TBL] [Abstract][Full Text] [Related]
56. Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis. A randomized controlled trial. Campieri M; De Franchis R; Bianchi Porro G; Ranzi T; Brunetti G; Barbara L Scand J Gastroenterol; 1990 Jul; 25(7):663-8. PubMed ID: 2204103 [TBL] [Abstract][Full Text] [Related]
57. Factors affecting recurrence after surgery for Crohn's disease. Yamamoto T World J Gastroenterol; 2005 Jul; 11(26):3971-9. PubMed ID: 15996018 [TBL] [Abstract][Full Text] [Related]
58. Placebo-controlled trial of oral 5-ASA in relapse prevention of Crohn's disease. Brignola C; Iannone P; Pasquali S; Campieri M; Gionchetti P; Belluzzi A; Basso O; Miglioli M; Barbara L Dig Dis Sci; 1992 Jan; 37(1):29-32. PubMed ID: 1728527 [TBL] [Abstract][Full Text] [Related]
59. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Lochs H; Mayer M; Fleig WE; Mortensen PB; Bauer P; Genser D; Petritsch W; Raithel M; Hoffmann R; Gross V; Plauth M; Staun M; Nesje LB Gastroenterology; 2000 Feb; 118(2):264-73. PubMed ID: 10648454 [TBL] [Abstract][Full Text] [Related]
60. Mesalazine as maintenance treatment in Crohn's disease. Vos J; Lesterhuis W Gastroenterology; 1994 Feb; 106(2):553-4. PubMed ID: 8299923 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]